Equities Analysts Offer Predictions for UNCY Q1 Earnings

Key Points

• Brookline Capital Markets expects UNCY Q1 2026 EPS of ($0.32) and projects a dramatic turnaround from FY2026 EPS of ($1.39) to FY2027 EPS of $5.68, signaling large modelled improvement ahead.
• Unicycive reported ($0.82) EPS for the quarter ended March 30, missing estimates of ($0.46), and the stock trades around $6.65 with a market cap of roughly $167.8 million.
• Analyst coverage is mixed but tilted positive—four Buys and one Sell—resulting in an average rating of Moderate Buy and an average price target of $25.67.

Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Free Report) - Analysts at Brookline Capital Markets issued their Q1 2026 earnings per share estimates for Unicycive Therapeutics in a research note issued on Tuesday, April 7th. Brookline Capital Markets analyst K. Raja expects that the company will post earnings per share of ($0.32) for the quarter. The consensus estimate for Unicycive Therapeutics' current full-year earnings is ($0.23) per share. Brookline Capital Markets also issued estimates for Unicycive Therapeutics' Q3 2026 earnings at ($0.39) EPS, Q4 2026 earnings at ($0.34) EPS, FY2026 earnings at ($1.39) EPS, FY2027 earnings at $5.68 EPS, FY2028 earnings at $4.35 EPS, FY2029 earnings at $5.01 EPS and FY2030 earnings at $2.93 EPS.

UNCY has been the subject of a number of other research reports. Westpark Capital assumed coverage on Unicycive Therapeutics in a research report on Thursday, February 19th. They set a "buy" rating for the company. Guggenheim reduced their price objective on Unicycive Therapeutics from $46.00 to $40.00 and set a "buy" rating for the company in a research report on Thursday, April 2nd. Benchmark reduced their price objective on Unicycive Therapeutics from $21.00 to $15.00 and set a "speculative buy" rating for the company in a research report on Monday. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Unicycive Therapeutics in a research report on Friday, March 27th. Four research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, Unicycive Therapeutics currently has an average rating of "Moderate Buy" and an average price target of $25.67.

Unicycive Therapeutics Trading Up 3.1%

UNCY opened at $6.65 on Friday. The stock has a market cap of $167.83 million, a price-to-earnings ratio of -3.06 and a beta of 1.81. Unicycive Therapeutics has a 1 year low of $3.71 and a 1 year high of $11.00. The stock has a fifty day moving average price of $6.64 and a 200 day moving average price of $5.88.

Unicycive Therapeutics (NASDAQ:UNCY - Get Free Report) last released its quarterly earnings data on Monday, March 30th. The company reported ($0.82) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.46) by ($0.36).

Institutional Trading of Unicycive Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in UNCY. Lazard Asset Management LLC acquired a new stake in shares of Unicycive Therapeutics in the second quarter worth about $55,000. JPMorgan Chase & Co. lifted its position in shares of Unicycive Therapeutics by 11,698.4% in the second quarter. JPMorgan Chase & Co. now owns 21,709 shares of the company's stock worth $104,000 after buying an additional 21,525 shares during the last quarter. Citadel Advisors LLC acquired a new position in shares of Unicycive Therapeutics during the 3rd quarter worth about $182,000. Quadrature Capital Ltd acquired a new position in shares of Unicycive Therapeutics during the 4th quarter worth about $226,000. Finally, State Street Corp lifted its position in shares of Unicycive Therapeutics by 19.0% during the 4th quarter. State Street Corp now owns 65,227 shares of the company's stock worth $376,000 after purchasing an additional 10,400 shares during the last quarter. Institutional investors and hedge funds own 40.42% of the company's stock.

About Unicycive Therapeutics

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.